Top Stocks
Dividend Investing
ETFs
Stock Comparison
About Us
Working with TipRanks
Follow Us
Viracta Therapeutics (VIRX)
NASDAQ:VIRX
Viracta Therapeutics (VIRX) Stock Price & Analysis
655 Followers
VIRX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.21 - $5.75
Previous Close$1.4
Volume42.00K
Average Volume (3M)87.73K
Market Cap
$53.78M
Enterprise Value-$6.66M
Total Cash (Recent Filing)$91.04M
Total Debt (Recent Filing)$25.16M
Price to Earnings (P/E)-1.1
Beta0.88
Next Earnings
May 10, 2023EPS Estimate
-$0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.30
Shares Outstanding38,410,935
10 Day Avg. Volume54,350
30 Day Avg. Volume87,730
Standard Deviation0.33
R-Squared0.00230
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)0.97
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-1.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.14
Forecast
1Y Price Target
$18.00Price Target Upside1185.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Viracta Therapeutics News
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Product Monthly Users
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
VIRX FAQ
What was Viracta Therapeutics’s price range in the past 12 months?
Viracta Therapeutics lowest stock price was $1.21 and its highest was $5.75 in the past 12 months.
What is Viracta Therapeutics’s market cap?
Currently, no data Available
When is Viracta Therapeutics’s upcoming earnings report date?
Viracta Therapeutics’s upcoming earnings report date is May 10, 2023 which is in 44 days.
How were Viracta Therapeutics’s earnings last quarter?
Viracta Therapeutics released its earnings results on Mar 13, 2023. The company reported -$0.27 earnings per share for the quarter, beating the consensus estimate of -$0.364 by $0.094.
Is Viracta Therapeutics overvalued?
According to Wall Street analysts Viracta Therapeutics’s price is currently Undervalued.
Does Viracta Therapeutics pay dividends?
Viracta Therapeutics does not currently pay dividends.
What is Viracta Therapeutics’s EPS estimate?
Viracta Therapeutics’s EPS estimate is -$0.32.
How many shares outstanding does Viracta Therapeutics have?
Viracta Therapeutics has 38,410,934 shares outstanding.
What happened to Viracta Therapeutics’s price movement after its last earnings report?
Viracta Therapeutics reported an EPS of -$0.27 in its last earnings report, beating expectations of -$0.364. Following the earnings report the stock price went up 2.941%.
Which hedge fund is a major shareholder of Viracta Therapeutics?
Among the largest hedge funds holding Viracta Therapeutics’s share is Aisling Capital Management LP. It holds Viracta Therapeutics’s shares valued at 421K.
---
Viracta Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$18.00 (1185.71% Upside)
$18.00 (1185.71% Upside)
Hedge Fund Trend
Decreased
By 100.0 Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.6%
Last 30 Days ▼ 3.0%
Last 30 Days ▼ 3.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-63.44%
12-Months-Change
Fundamentals
Return on Equity
-63.29%
Trailing 12-Months
Asset Growth
-11.57%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Viracta Therapeutics
Sunesis Pharmaceuticals, Inc. engages in the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. The firms activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The company was founded on February 10, 1998 and is headquartered in South San Francisco, CA.
---
Top 5 ETFs holding VIRX
Currently, no data available
Please return soon. This page is being updated.
Up to five ETFs with an Outperform Smart Score that hold VIRX. The ETFs are listed according to market value of VIRX within the ETF
---
Aziyo Biologics
―
XBiotech
―
Shattuck Labs
―
Spectrum Pharmaceuticals
―
vTv Therapeutics
―
---